Loricrin is expressed in the granular layer of all keratinized epithelial cells of mammals tested including oral, esophageal and stomach mucosa of rodents, tracheal squamous metaplasia of vitamin A deficient hamster and estrogen induced squamous vaginal epithelium of rats.[6]
^Hohl D, Ruf Olano B, de Viragh PA, Huber M, Detrisac CJ, Schnyder UW, Roop DR (1993). "Expression patterns of loricrin in various species and tissues". Differentiation. 54 (1): 25–34. doi:10.1111/j.1432-0436.1993.tb01585.x. PMID8405772.
Further reading
Ishida-Yamamoto A, Takahashi H, Iizuka H (1998). "Loricrin and human skin diseases: molecular basis of loricrin keratodermas". Histol. Histopathol. 13 (3): 819–26. PMID9690138.
Ishida-Yamamoto A (2003). "Loricrin keratoderma: a novel disease entity characterized by nuclear accumulation of mutant loricrin". J. Dermatol. Sci. 31 (1): 3–8. doi:10.1016/S0923-1811(02)00143-3. PMID12615358.
Ishida-Yamamoto A, Hohl D, Roop DR, et al. (1994). "Loricrin immunoreactivity in human skin: localization to specific granules (L-granules) in acrosyringia". Arch. Dermatol. Res. 285 (8): 491–8. doi:10.1007/BF00376822. PMID8274037. S2CID9857068.
Maestrini E, Monaco AP, McGrath JA, et al. (1996). "A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel's syndrome". Nat. Genet. 13 (1): 70–7. doi:10.1038/ng0596-70. PMID8673107. S2CID9108586.
Richard G, Brown N, Smith LE, et al. (2000). "The spectrum of mutations in erythrokeratodermias--novel and de novo mutations in GJB3". Hum. Genet. 106 (3): 321–9. doi:10.1007/s004390051045 (inactive 1 November 2024). PMID10798362.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)